143 related articles for article (PubMed ID: 20560956)
1. Notch signalling in primary cutaneous CD30+ lymphoproliferative disorders: a new therapeutic approach?
Kamstrup MR; Biskup E; Gniadecki R
Br J Dermatol; 2010 Oct; 163(4):781-8. PubMed ID: 20560956
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
Biskup E; Kamstrup MR; Manfé V; Gniadecki R
Br J Dermatol; 2013 Mar; 168(3):504-12. PubMed ID: 23445313
[TBL] [Abstract][Full Text] [Related]
3. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
4. Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders.
Yamaguchi T; Ohshima K; Karube K; Kawano R; Nakayama J; Suzumiya J; Kikuchi M
Br J Dermatol; 2006 May; 154(5):904-9. PubMed ID: 16634894
[TBL] [Abstract][Full Text] [Related]
5. Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer.
Lee HW; Kim SJ; Choi IJ; Song J; Chun KH
Clin Exp Metastasis; 2015 Aug; 32(6):593-603. PubMed ID: 26134677
[TBL] [Abstract][Full Text] [Related]
6. Gamma-secretase inhibitors suppress the growth of leukemia and lymphoma cells.
Kogoshi H; Sato T; Koyama T; Nara N; Tohda S
Oncol Rep; 2007 Jul; 18(1):77-80. PubMed ID: 17549349
[TBL] [Abstract][Full Text] [Related]
7. Notch1 downregulation combined with interleukin-24 inhibits invasion and migration of hepatocellular carcinoma cells.
Han B; Liu SH; Guo WD; Zhang B; Wang JP; Cao YK; Liu J
World J Gastroenterol; 2015 Sep; 21(33):9727-35. PubMed ID: 26361419
[TBL] [Abstract][Full Text] [Related]
8. Potential involvement of Notch1 signalling in the pathogenesis of primary cutaneous CD30-positive lymphoproliferative disorders.
Kamstrup MR; Ralfkiaer E; Skovgaard GL; Gniadecki R
Br J Dermatol; 2008 Apr; 158(4):747-53. PubMed ID: 18241263
[TBL] [Abstract][Full Text] [Related]
9. KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.
Battistella M; Janin A; Jean-Louis F; Collomb C; Leboeuf C; Sicard H; Bonnafous C; Dujardin A; Ram-Wolff C; Kadin ME; Bensussan A; Bagot M; Michel L
Br J Dermatol; 2016 Aug; 175(2):325-33. PubMed ID: 27037558
[TBL] [Abstract][Full Text] [Related]
10. GSI-I has a better effect in inhibiting hepatocellular carcinoma cell growth than GSI-IX, GSI-X, or GSI-XXI.
Shen Y; Lv D; Wang J; Yin Y; Miao F; Dou F; Zhang J
Anticancer Drugs; 2012 Aug; 23(7):683-90. PubMed ID: 22569108
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of gamma-secretase affects proliferation of leukemia and hepatoma cell lines through Notch signaling.
Suwanjunee S; Wongchana W; Palaga T
Anticancer Drugs; 2008 Jun; 19(5):477-86. PubMed ID: 18418214
[TBL] [Abstract][Full Text] [Related]
12. Gamma-secretase inhibitors exerts antitumor activity via down-regulation of Notch and Nuclear factor kappa B in human tongue carcinoma cells.
Yao J; Duan L; Fan M; Wu X
Oral Dis; 2007 Nov; 13(6):555-63. PubMed ID: 17944672
[TBL] [Abstract][Full Text] [Related]
13. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
Shepherd C; Banerjee L; Cheung CW; Mansour MR; Jenkinson S; Gale RE; Khwaja A
Leukemia; 2013 Mar; 27(3):650-60. PubMed ID: 23038273
[TBL] [Abstract][Full Text] [Related]
14. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy.
Liu J; Mao Z; Huang J; Xie S; Liu T; Mao Z
Biochem Biophys Res Commun; 2014 Feb; 444(4):670-5. PubMed ID: 24502949
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative effects of γ-secretase inhibitor, a Notch signalling inhibitor, in multiple myeloma cells and its molecular mechanism of action.
Hu J; Zhu X; Lu Q
J Int Med Res; 2013 Aug; 41(4):1017-26. PubMed ID: 23839278
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.
Lewis HD; Leveridge M; Strack PR; Haldon CD; O'neil J; Kim H; Madin A; Hannam JC; Look AT; Kohl N; Draetta G; Harrison T; Kerby JA; Shearman MS; Beher D
Chem Biol; 2007 Feb; 14(2):209-19. PubMed ID: 17317574
[TBL] [Abstract][Full Text] [Related]
18. γ-Secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets.
Dorneburg C; Goß AV; Fischer M; Roels F; Barth TF; Berthold F; Kappler R; Oswald F; Siveke JT; Molenaar JJ; Debatin KM; Beltinger C
Oncotarget; 2016 Sep; 7(39):62799-62813. PubMed ID: 27588497
[TBL] [Abstract][Full Text] [Related]
19. γ-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation.
Rosati E; Sabatini R; De Falco F; Del Papa B; Falzetti F; Di Ianni M; Cavalli L; Fettucciari K; Bartoli A; Screpanti I; Marconi P
Int J Cancer; 2013 Apr; 132(8):1940-53. PubMed ID: 23001755
[TBL] [Abstract][Full Text] [Related]
20. GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.
Meng X; Matlawska-Wasowska K; Girodon F; Mazel T; Willman CL; Atlas S; Chen IM; Harvey RC; Hunger SP; Ness SA; Winter SS; Wilson BS
Leukemia; 2011 Jul; 25(7):1135-46. PubMed ID: 21494254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
